Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MGROF | OTC Markets | USD | Delayed | |
MGRO | CBOE Canada | CAD | Real-time | |
MGRO | TSXV | CAD | Delayed |
For the three months ended 31 March 2022, MustGrow Biologics Corp revenues increased from C$0K to C$1K. Net loss increased 65% to C$1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-Based Compensation increase from C$60K to C$207K (expense), Management compensation increase of 51% to C$219K (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0.01 | 0 |
Gross Profit | ||||
Operating Income | -1 | -1.08 | -0.68 | -0.65 |
Net Income | -1.01 | -1.1 | -0.7 | -0.66 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 9.42 | 9.7 | 3.1 | 3.25 |
Total Liabilities | 1.26 | 1.25 | 1.11 | 1.04 |
Total Equity | 8.15 | 8.46 | 2 | 2.21 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -0.79 | -2.41 | -1.67 | -1.18 |
Cash From Investing Activities | ||||
Cash From Financing Activities | 0.5 | 8.72 | 1.43 | 1.05 |
Net Change in Cash | -0.29 | 6.31 | -0.25 | -0.13 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review